Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.76 |
| ▸ | MEN1 | O00255 | 6/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.66 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31668740 | 0.97 | MDM2 (0.95) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL23999548 | 0.91 | MDM2 (0.83) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL305498 | 0.91 | TAAR1 (1.00) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL5851814 | 0.87 | MDM2 (0.76) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL13552998 | 0.87 | KMT2A (1.00) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL13554610 | 0.87 | MDM2 (0.76) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL4917143 | 0.87 | KMT2A (1.00) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL3460997 | 0.87 | MAPT (0.76) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL4717455 | 0.87 | MDM2 (0.76) | MDM2TAAR1KMT2AMEN1RAB9A | |
| SCHEMBL7789976 | 0.86 | MDM2 (0.75) | MDM2TAAR1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023176554-A1 | COGNITIVE-FUNCTION-IMPROVING AGENT | 国立大学法人東北大学 | 2023-09-21 | — | — | WO | claimed |
| WO-2023176554-A1 | COGNITIVE-FUNCTION-IMPROVING AGENT | 国立大学法人東北大学 | 2023-09-21 | — | — | WO | disclosed |
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-09-19 | — | — | US | disclosed |
| WO-2019073484-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE (IN) | 2019-04-18 | — | — | WO | disclosed |
| US-8729107-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729107-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2014-05-20 | — | — | US | disclosed |
| US-8097638-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097638-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2011-06-02 | — | — | US | disclosed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PURDUE RESEARCH FOUNDATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-7244748-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244748-B2 | Pyridines for treating injured mammalian nerve tissue | PURDUE RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039490-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | P2RY4, INA, PMP22 | MDM2 3943/4885TAAR1 1150/4885KMT2A 1451/4885 |
| US-20190284171-A1 | METHOD OF CONVERTING CARBON DIOXIDE INTO CARBONYL COMPOUNDS | CBR3, CBR1, NOX3 | MDM2 2944/4885TAAR1 3990/4885KMT2A 2913/4885 |
| US-20110130429-A1 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE | PMP22, SMN1; SMN2, MUSK | MDM2 2189/4885TAAR1 1722/4885KMT2A 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.